Chinese interpretation of European Neuroendocrine Tumour Society 2023 guidance for nonfunctioning pancreatic neuroendocrine tumours

doi:10.16139/j.1007-9610.2024.01.04

Abstract

Abstract:

This ENETS guidance for well-differentiated nonfunctioning pancreatic neuroendocrine tumours (NF-Pan-NET), which published on Journal of Neuroendocrinology (2023), has been developed by a multidisciplinary working group, and provides up-to-date and practical advice on the management of these tumours. In this guideline, the authors discussed 10 troublesome questions about clinical practice, and summarized the extensive experience of their centers treating patients with NF-Pan-NET, and suggested that multidisciplinary participation is an essential part of NF-Pan-NET diagnosis and treatment. This paper aims to interpret the key contents of the guidelines in order to provide standardized clinical diagnosis and treatment procedures in NF-Pan-NET.

Key words: Nonfunctioning pancreatic neuroendocrine tumour, Guideline, Diagnostics, Treatment

CLC Number:

R735.9

HAN Liang, LIU Haonan, WU Zheng. Chinese interpretation of European Neuroendocrine Tumour Society 2023 guidance for nonfunctioning pancreatic neuroendocrine tumours[J]. Journal of Surgery Concepts & Practice, 2024, 29(01): 14-26.

Figures/Tables 3

Tab 1

Tab 2

Fig 1

References 52

[1]	KOS-KUDŁA B, CASTAÑO J P, DENECKE T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours[J]. J Neuroendocrinol, 2023, 35(12):e13343.
[2]	YANG Z, SHI G. Comparative outcomes of pancreatic neuroendocrine neoplasms: a population-based analysis of the SEER database[J]. Eur J Surg Oncol, 2022, 48(10):2181-2187.
[3]	AYSAL A, AGALAR C, EGELI T, et al. Reconsideration of clinicopathologic prognostic factors in pancreatic neuroendocrine tumors for better determination of adverse prognosis[J]. Endocr Pathol, 2021, 32(4):461-472. doi: 10.1007/s12022-021-09687-w pmid: 34283399
[4]	NAGTEGAAL I D, ODZE R D, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2):182-188. doi: 10.1111/his.13975 pmid: 31433515
[5]	BELLIZZI A M. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?[J]. Hum Pathol, 2020,96:8-33.
[6]	PUSCEDDU S, PRINZI N, TAFUTO S, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2022, 5(2):e220290.
[7]	DAM G, GRØNBÆK H, SORBYE H, et al. Prospective study of chromogranin A as a predictor of progression in patients with pancreatic, small-intestinal, and unknown primary neuroendocrine tumors[J]. Neuroendocrinology, 2020, 110(3-4):217-224. doi: 10.1159/000503833 pmid: 31578011
[8]	PAVEL M, ÖBERG K, FALCONI M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7):844-860. doi: S0923-7534(20)36394-8 pmid: 32272208
[9]	MALCZEWSKA A, KOS-KUDŁA B, KIDD M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors[J]. Adv Med Sci, 2020, 65(1):18-29.
[10]	MALCZEWSKA A, WITKOWSKA M, WÓJCIK-GIERTUGA M, et al. Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS center of excellence experience[J]. Neuroendocrinology, 2021, 111(4):304-319.
[11]	ÖBERG K, CALIFANO A, STROSBERG J R, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood[J]. Ann Oncol, 2020, 31(2):202-212. doi: S0923-7534(19)39084-2 pmid: 31959337
[12]	MODLIN I M, KIDD M, FALCONI M, et al. A multi-genomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility[J]. Ann Oncol, 2021, 32(11):1425-1433.
[13]	KOS-KUDŁA B, FOLTYN W, MALCZEWSKA A, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)][J]. Endokrynol Pol, 2022, 73(3):387-454.
[14]	BLÁZQUEZ-ENCINAS R, MORENO-MONTILLA M T, GARCÍA-VIOQUE V, et al. The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities[J]. Rev Endocr Metab Disord, 2023, 24(2):267-282.
[15]	KOS-KUDŁA B, ROSIEK V, BOROWSKA M, et al. Pancreatic neuroendocrine neoplasms - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)][J]. Endokrynol Pol, 2022, 73(3):491-548.
[16]	CARLSEN E A, JOHNBECK C B, LOFT M, et al. Semiautomatic tumor delineation for evaluation of ⁶⁴Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume[J]. J Nucl Med, 2021, 62(11):1564-1570.
[17]	BINDERUP T, KNIGGE U, JOHNBECK C B, et al. ¹⁸F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-Year follow-up study[J]. J Nucl Med, 2021, 62(6):808-815.
[18]	RICCI C, PARTELLI S, LANDONI L, et al. Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis[J]. Br J Surg, 2021, 108(7):811-816. doi: 10.1093/bjs/znaa141 pmid: 33724300
[19]	HEIDSMA C M, ENGELSMAN A F, VAN DIEREN S, et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA)[J]. Br J Surg, 2021, 108(8):888-891. doi: 10.1093/bjs/znab088 pmid: 33783475
[20]	PARTELLI S, MASSIRONI S, ZERBI A, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial[J]. Br J Surg, 2022, 109(12):1186-1190.
[21]	BOLM L, PISUCHPEN N, QADAN M, et al. Prediction of R status in resections for pancreatic cancer using simplified radiological criteria[J]. Ann Surg, 2022, 276(2):215-221. doi: 10.1097/SLA.0000000000005433 pmid: 36036988
[22]	PARTELLI S, MUFFATTI F, ANDREASI V, et al. A single-center prospective observational study investiga-ting the accuracy of preoperative diagnostic procedures in the assessment of lymph node metastases in nonfunctioning pancreatic neuroendocrine tumors[J]. Ann Surg, 2022, 276(5):921-928.
[23]	PARTELLI S, ANDREASI V, RANCOITA P M V, et al. Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting[J]. Surg Endosc, 2021, 35(1):165-173.
[24]	DONG D H, ZHANG X F, LOPEZ-AGUIAR A G, et al. Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection[J]. HPB (Oxford), 2020, 22(8):1149-1157.
[25]	ZHOU B, XIANG J, JIN M, et al. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors[J]. BMC Cancer, 2021, 21(1):334. doi: 10.1186/s12885-021-08062-6 pmid: 33789624
[26]	HEIDSMA C M, VAN ROESSEL S, VAN DIEREN S, et al. International validation of a nomogram to predict recurrence after resection of grade 1 and 2 nonfunctioning pancreatic neuroendocrine tumors[J]. Neuroendocrino-logy, 2022, 112(6):571-579.
[27]	FUSAI G K, TAMBURRINO D, PARTELLI S, et al. Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study[J]. Surgery, 2021, 169(5):1093-1101.
[28]	PARTELLI S, BERTANI E, BARTOLOMEI M, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms[J]. Surgery, 2018, 163(4):761-767.
[29]	PARGHANE R V, BHANDARE M, CHAUDHARI V, et al. Surgical feasibility, determinants, and overall efficacy of neoadjuvant ¹⁷⁷Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors[J]. J Nucl Med, 2021, 62(11):1558-1563.
[30]	BAUDIN EWT, BERON A, SMITH D, et al. 887O first multicentric randomized phase Ⅱ trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with ¹⁷⁷Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial[J]. Ann Oncol, 2022, 33:S410-S416.
[31]	CLEMENT D, NAVALKISSOOR S, SRIRAJASKANTHAN R, et al. Efficacy and safety of ¹⁷⁷Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study[J]. Eur J Nucl Med Mol Imaging, 2022, 49(10):3529-3537.
[32]	STARR J S, SONBOL M B, HOBDAY T J, et al. Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights[J]. Onco Targets Ther, 2020,13:3545-3555.
[33]	ZHANG J, KULKARNI H R, SINGH A, et al. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients[J]. J J Nucl Med, 2019, 60(3):377-385.
[34]	CARLSEN E A, FAZIO N, GRANBERG D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study[J]. Endocr Relat Cancer, 2019, 26(2):227-239.
[35]	THANG S P, LUNG M S, KONG G, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN)-a single-institution retrospective analysis[J]. Eur J Nucl Med Mol Imaging, 2018, 45(2):262-277.
[36]	ZEMCZAK A, GUT P, PAWLAK D, et al. The safety and efficacy of the repeated PRRT with [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTATATE in patients with NET[J]. Int J Endocrinol, 2021,2021:6615511.
[37]	HARRIS P E, ZHERNOSEKOV K. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?[J]. Front Endocrinol (Lausanne), 2022,13:941832.
[38]	STROSBERG J, LEEUWENKAMP O, SIDDIQUI M K. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis[J]. Cancer Treat Rev, 2021,93:102141.
[39]	MEROLA E, ALONSO GORDOA T, ZHANG P, et al. Somatostatin analogs for pancreatic neuroendocrine tumors: any benefit when Ki-67 is ≥10%?[J] Oncologist, 2021, 26(4):294-301. doi: 10.1002/onco.13633 pmid: 33301235
[40]	JONASCH E, DONSKOV F, ILIOPOULOS O, et al. Belzutifan for renal cell carcinoma in von hippel-lindau disease[J]. N Engl J Med, 2021, 385(22):2036-2046.
[41]	KUNZ P L, GRAHAM N T, CATALANO P J, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)[J]. J Clin Oncol, 2023, 41(7):1359-1369.
[42]	CHAN D L, BERGSLAND E K, CHAN J A, et al. Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: a multicenter retrospective review[J]. Oncologist, 2021, 26(11):950-955.
[43]	LAHNER H, MATHEW A, KLOCKER A L, et al. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy[J]. Endocrine, 2022, 75(1):293-302.
[44]	DE MESTIER L, WALTER T, EVRARD C, et al. Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor[J]. Neuroendocrinology, 2020, 110(1-2):83-91. doi: 10.1159/000500862 pmid: 31071715
[45]	STROSBERG J, KUNZ P L, HENDIFAR A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate: an analysis of the NETTER-1 study[J]. Eur J Nucl Med Mol Imaging, 2020, 47(10):2372-2382.
[46]	MEROLA E, PRASAD V, PASCHER A, et al. Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options[J]. Neuroendocrinology, 2020, 110(6):517-524. doi: 10.1159/000503144 pmid: 31484182
[47]	SALAZAR RTS, KROGH M, TEULE A, et al. Rando-mized open label phase Ⅲ study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: the SEQ-TOR study (GETNE 1206)[J]. Ann Oncol, 2022, 33(suppl 7):S808-S869.
[48]	VAN DEN BROEK M F M, VAN NESSELROOIJ B P M, PIETERMAN C R C, et al. Clues for genetic anticipation in multiple endocrine neoplasia type 1[J]. J Clin Endocrinol Metab, 2020, 105(7):dgaa257.
[49]	CUTHBERTSON D J, BARRIUSO J, LAMARCA A, et al. The impact of 68Gallium DOTA PET/CT in mana-ging patients with sporadic and familial pancreatic neuroendocrine tumours[J]. Front Endocrinol (Lausanne), 2021,12:654975.
[50]	PIETERMAN C R C, VALK G D. Update on the clinical management of multiple endocrine neoplasia type 1[J]. Clin Endocrinol (Oxf), 2022, 97(4):409-423.
[51]	SADOWSKI S M, PIETERMAN C R C, PERRIER N D, et al. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature[J]. Endocr Relat Cancer, 2020, 27(6):R145-R161.
[52]	PULVIRENTI A, JAVED A A, LANDONI L, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6):1051-1057.

问题	内容
Q1	如何定义及描述NF-Pan-NET的特征?
Q2	NF-Pan-NET病人应进行哪些生化检查(目前和新型生物标志物)?
Q3	NF-Pan-NET 病人最适合的影像学检查是什么?
Q4	NF-Pan-NET病人最适合的手术方式是什么?
Q5	PRRT在NF-Pan-NET病人中的特定作用是什么?
Q6	生物疗法和分子靶向治疗在NF-Pan-NET的作用是什么?
Q7	化疗在NF-Pan-NET治疗中的作用?
Q8	进展期NF-Pan-NET最合适的一线治疗策略是什么?其治疗选择顺序是什么?
Q9	MEN1病人如何管理?
Q10	NF-Pan-NET推荐的随访策略是什么?

证据等级	治疗	诊断
1a	同质性较好的RCT系统评价	同质性良好的一级诊断研究系统评价；具有良好参考标准的临床决策规则/队列研究
1b	单个RCT（置信区间窄）
2a	队列研究的系统评价	同质的二级以上诊断研究的系统评价
2b	单个队列研究或低质量RCT	具有良好参考标准的探索性队列研究；推导后的临床决策规则
3a	同质性较好的病例对照研究系统评价	3b或更高级研究的同质系统评价
3b	单个病例对照研究	非连续研究；或没有一致应用的参考标准
4	系列病例分析或质量较差的病例对照研究	病例对照研究，较差或非独立的参考标准
5	未经明确分析评价的专家意见	未经明确分析评价的专家意见
推荐等级
A	高质量
B	中等质量
C	低质量
D	极低质量